MENU

Can Orthofix Medical (OFIX) Stock Reach $11?

a developer of surgical products to the spine and orthopedic markets

A.I.Advisor
published price charts
A.I.Advisor
Nov 18, 2026

Can Orthofix Medical (OFIX) Stock Reach $11?

Orthofix Medical Inc. (OFIX), a global medical device company focused on spine and orthopedic solutions, has seen its shares slide toward the lower end of a wide 52-week range. With a fresh round of analyst price target cuts following its third-quarter report, investors are asking whether the stock can recover. The central question: can OFIX reach $11?

Key Takeaways

  • The central target of $11 is the arithmetic mean of four verified analyst price targets, rounded from $10.75.
  • The analyst price target range runs from a low of $9 to a high of $13, reflecting a meaningful spread in views.
  • The latest verified closing price is about $6.67, so reaching $11 would require roughly a 65% move.
  • Recent targets were cut sharply after a third-quarter report that analysts described as disappointing on revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
  • Supportive factors include a mostly completed SeaSpine integration, new product momentum, and activist investor accumulation.
  • Risks include persistent net losses, execution concerns, and downward-trending analyst revisions.
  • For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
  • Readers looking for AI-driven trade ideas can explore Trending AI Robots.

Analyst Price Targets and Consensus View

Four current, attributable analyst targets were reviewed. After the third-quarter 2026 report, three firms revised their targets in the same session: Barrington's Michael Petusky lowered his target to $10 (Outperform), TD Cowen cut to $9 (Hold), and Canaccord Genuity's Caitlin Roberts reiterated Buy while trimming to $11. Stifel's Thomas Stephan held a $13 target (Buy) from August, representing the high end of the range. Together these yield a low-to-high range of $9 to $13 and a simple average of $10.75, rounded to a central target of $11.

The spread between the cautious $9 (TD Cowen) and the more constructive $13 (Stifel) shows genuine disagreement about how quickly Orthofix can improve profitability. The overall tone is tilted toward Buy or Outperform ratings, but the direction of revisions has been consistently downward, as analysts cite slower-than-expected revenue and a longer path to margin goals.

Current Market Position and Path Toward the Target

With a latest verified price near $6.67, moving to $11 implies upside of approximately 65%, a very large move by any standard. The stock trades near the bottom of a 52-week range of roughly $6.52 to $16.57 and carries a market capitalization around $270 million. The path toward $11 would likely require the company to demonstrate sustained revenue growth, progress on adjusted EBITDA, and a return of investor confidence after repeated guidance recalibrations.

What Could Support a Move Toward the Target

Several factors could support a recovery. Orthofix's integration of SeaSpine, acquired in 2023, is largely complete, and management has signaled improved demand and reaffirmed targets for positive free cash flow and EBITDA margin expansion over the coming years. The 7D FLASH spine navigation platform is a longer-term growth catalyst analysts have highlighted. Activist investor Engine Capital has accumulated shares, and insider buying has been positive. A deep discount to medical-device peers on an EV/EBITDA (enterprise value to EBITDA) basis gives a valuation-driven argument for upside if execution improves.

What Could Prevent the Target From Being Reached

The principal obstacle is execution. Orthofix remains unprofitable, with a current-year EPS (earnings per share) estimate near negative $1.18 and a P/E (price-to-earnings) ratio that is not meaningful on trailing losses. The third-quarter report was characterized as disappointing on revenue and adjusted EBITDA, prompting broad target reductions. Slowing demand, competitive pressure in spine, macroeconomic uncertainty around hospital capital spending, and continued valuation compression could all keep the stock well below $11.

Technical Levels and Market Structure

Orthofix is trading just above its 52-week low near $6.52, which now serves as the most important support level. A decisive break below that area would open fresh downside. On the upside, the $10 psychological level sits just below the central target, while the $13 high-end analyst target and the broader $16 to $17 zone, near former highs, represent the most durable resistance levels. The long-term trend remains firmly downward until the stock can reclaim and hold higher ranges.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the exact horizon varies by firm. Key items to monitor include upcoming quarterly earnings and guidance, analyst target revisions, adjusted EBITDA trajectory, free cash flow generation, new product launches and FDA (Food and Drug Administration) clearances, and any further accumulation by activist or insider holders. Changes in hospital and surgical procedure volumes are also directly relevant to demand.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, track existing positions, and spot changing trends more efficiently than manual screening allows. For those following OFIX, these tools can add a systematic layer to fundamental research.

Final Assessment

The $11 central target, derived from a four-analyst average of $10.75, sits well above the current price near $6.67 and would require a move of roughly 65%. The strongest supports are a completed SeaSpine integration, new product catalysts, activist interest, and a discounted valuation, while the biggest obstacles are persistent losses, disappointing recent results, and a steady stream of downward analyst revisions. The wide $9-to-$13 range underscores genuine uncertainty. Whether OFIX approaches $11 depends primarily on execution and margin improvement, which investors should continue to monitor closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

OFIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OFIX has been loosely correlated with SYK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if OFIX jumps, then SYK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OFIX
1D Price
Change %
OFIX100%
-4.26%
SYK - OFIX
50%
Loosely correlated
-0.98%
ENOV - OFIX
48%
Loosely correlated
-2.90%
PODD - OFIX
48%
Loosely correlated
-2.96%
ATEC - OFIX
47%
Loosely correlated
-3.19%
SIBN - OFIX
46%
Loosely correlated
-0.08%
More

Groups containing OFIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OFIX
1D Price
Change %
OFIX100%
-4.26%
Health Services
category (238 stocks)
4%
Poorly correlated
-2.69%
Medical/Nursing Services
category (138 stocks)
4%
Poorly correlated
-3.38%